Status:
COMPLETED
Prasugrel Re-load Strategies
Lead Sponsor:
University of Florida
Conditions:
Coronary Artery Disease
Eligibility:
All Genders
18-74 years
Phase:
PHASE4
Brief Summary
A higher degree of platelet inhibition remains the goal of peri-interventional and long-term anti-thrombotic therapy in patients with coronary artery disease. In clinical practice, patients undergoing...
Eligibility Criteria
Inclusion
- Patients with angiographically documented coronary artery disease.
- Age between 18 to 74 years
- On treatment with prasugrel 10mg/daily for at least 14 days.
Exclusion
- Blood dyscrasias or bleeding diathesis
- Antiplatelet treatment with clopidogrel or ticlopidine
- Recent antiplatelet treatment (\< 14 days) with a glycoprotein IIb/IIIa antagonist
- Platelet count \<100x106/µL
- Active bleeding or hemodynamic instability.
- Unstable angina, acute or recent (\<14 days) myocardial infarction.
- Serum creatinine \>2 mg/dL
- Baseline ALT \>2.5 times the upper limit of normal
- Oral anticoagulation with a coumarin derivative
- History of stroke, TIA or intracranial bleeding
- Weight \<60kg
- Pregnant females
Key Trial Info
Start Date :
August 1 2010
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
September 1 2011
Estimated Enrollment :
65 Patients enrolled
Trial Details
Trial ID
NCT01201772
Start Date
August 1 2010
End Date
September 1 2011
Last Update
January 18 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Florida
Jacksonville, Florida, United States, 32209